Ensayos clínicos

Inclusion Criteria:

• Understands the requirements of the study and provides written informed consent.
• prior to undergoing any study-related procedures.
• Subject is between the ages of 18 to 85 years old, inclusive.
• Has had and agrees to submit the results and images of a CT that shows some disease of the bowel or disease adjacent to bowel (e.g., peritoneal disease, carcinomatosis, omental caking or bowel inflammation), such that there is a reasonably high chance that the study CT scan could also show disease and which was:
  • conducted within 6 months prior to study entry;
  • conducted with IV and either positive or neutral oral contrast.
• Is willing and able to comply with protocol-specified CT scanning and visits to the clinic.
• Is able to lie flat with arms above head for 15 minutes and hold breath for 15 seconds.
• Is able to drink 1.2 liters of fluid within 45 minutes.
• Has good venous access as determined by the Investigator at screening.
• Is an outpatient who is able and willing to come to the clinic for study visits.

Exclusion Criteria:

• Has any co-morbidity that the Investigator judges will interfere with their ability to complete the study or undergo a quality CT scan; e.g., high risk of aspiration.
• Has a history of or is currently suffering from a known gastrointestinal motility disorder; e.g., severe constipation / gastroparesis, achalasia, pseudo-obstruction, etc.
• Has symptoms of a possible current bowel obstruction.
• Has a moderate to high risk of current bowel perforation.
• Subject should not schedule a GI diagnostic surgery or hospitalization for any procedure until after the Study follow-up on Day 14 day. However, if at the time of study entry, the subject has pre-planned a surgery or hospitalization, it may be allowed at the discretion of the PI provided it does not take place until after the subject completes the Day 3 ± 2 days visit.
• Has a contraindication (i.e. allergy) to IV or Oral CT contrast.
• If of child-bearing potential, has a confirmed pregnancy or a high probability of pregnancy at the time of screening.
• Has received an investigational therapeutic or diagnostic agent or been treated with an investigational device within the 30 days prior to enrollment.